# Orion Healthcare Equity Partners

> Orion Healthcare Equity Partners is a VC fund backing Health Care. See 1 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 1
- Last investment: Sep 2016
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.orhep.com

Orion Healthcare Equity Partners is a VC fund in Boston focused on Health Care and Biotechnology. Orion Healthcare Equity Management is a Venture Capital Firm focussed on health. Orion invested in Solexa (genetic sequencing), acquired by Illumina for $600 million in 2007. Orion funded PowderMed (DNA vaccine delivery), purchased by Pfizer.

## Contacts

5 contacts available for Orion Healthcare Equity Partners. Shizune tracks 3 team members at Orion Healthcare Equity Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/orion-healthcare-equity-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 100% |
| Biotechnology | 1 | 100% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bob Dean | Advisor | 0 | https://shizune.co/investors/profile/bob-dean-e061 |
| Daniel Wheeler L | Advisor | 0 | https://shizune.co/investors/profile/daniel-wheeler-l |
| Mark Carthy | Managing Partner | 2 | https://shizune.co/investors/profile/mark-carthy-3 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AnTolRx | At AnTolRx they are approaching the treatment of autoimmune diseases differently–through the development of novel nanoparticle-based therapies to promote antigen-specific immune tolerance. Standard therapies broadly suppress the immune system, inducing side effects that may include life threatening infections and tumors. Thus, there is an unmetclinical need for methods of targeted immune-regulation. Their proprietary drug development approach selectively targets pathogenic immune cells providing a unique tolerogenic signal to induce an anti-inflammatory phenotype and better treat diseases. | $4M | Series A | Sep 08, 2016 |  |

1 of 1 investments shown.

## Co-investors
- [Breakthrough T1D](https://shizune.co/investors/profile/jdrf) — VC Fund, 1 deal together
- [Pfizer Venture Investments](https://shizune.co/investors/profile/pfizer-venture-investments) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Orion Healthcare Equity Partners invest in?

Orion Healthcare Equity Partners invests primarily in Health Care and Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Orion Healthcare Equity Partners?

Public channels for Orion Healthcare Equity Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Orion Healthcare Equity Partners?

The team at Orion Healthcare Equity Partners includes Bob Dean (Advisor), Daniel Wheeler L (Advisor) and Mark Carthy (Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co